SCHEMBL5136633

SCHEMBL5136633

CCCCN(Cc1ccc(OCC)cc1)Cc1c(-c2ccc(OC)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 6/20 0.45
ATP4B P51164 6/20 0.45
DRD2 P14416 5/20 0.41
DRD3 P35462 5/20 0.41
C5AR1 P21730 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
BCHE P06276 3/20 0.39
CACNA2D1 P54289 1/20 0.39
PDE4B Q07343 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5070096 0.95 ATP4A (0.50) ATP4AATP4BDRD2DRD3HRH3
SCHEMBL647665 0.95 ATP4A (0.46) ATP4AATP4BDRD2DRD3C5AR1
SCHEMBL5135871 0.95 ATP4A (0.44) ATP4AATP4BDRD2DRD3C5AR1
SCHEMBL5136799 0.94 C5AR1 (0.43) ATP4AATP4BDRD2DRD3C5AR1
SCHEMBL5137164 0.94 C5AR1 (0.44) ATP4AATP4BDRD2DRD3C5AR1
SCHEMBL5135343 0.94 ATP4A (0.48) ATP4AATP4BDRD2DRD3HRH3
SCHEMBL5136000 0.93 ATP4A (0.42) ATP4AATP4BDRD2DRD3C5AR1
SCHEMBL5136763 0.93 KDM4E (0.43) ATP4AATP4BDRD2DRD3C5AR1
SCHEMBL5073977 0.93 ATP4A (0.46) ATP4AATP4BDRD2DRD3C5AR1
SCHEMBL5135885 0.92 MAPT (0.45) ATP4AATP4BDRD2DRD3C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed